National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Drospirenone/estetrol monohydrate (Drovelis®). HTA ID: 22073

Drospirenone/estetrol monohydrate is indicated for oral contraception.


NCPE Assessment Process Complete
Rapid review commissioned 07/12/2022
Rapid review completed 23/01/2023
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that drospirenone/estetrol monohydrate not be considered for reimbursement at the submitted price*.


*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.